Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Jin, Luming"'
Autor:
Huang, Lipeng, Chen, Chaoyang, Sun, Qingyu, Yu, Zhichen, Wang, Xiaoyan, Wang, Xinle, Yang, Shuoqi, Jin, Luming, Bu, Liang
Publikováno v:
Frontiers in Oncology; 2024, p1-9, 9p
Publikováno v:
Open Medicine, Vol 17, Iss 1, Pp 87-95 (2021)
Long noncoding RNA (lncRNA), specifically the upregulation of lncRNA NR2F1 antisense RNA 1 (NR2F1-AS1), has been involved in the progression of non-small cell lung cancer (NSCLC), but the mechanisms that underlie this remain unclear. In this study, t
Externí odkaz:
https://doaj.org/article/d688e619aa4d48f9935e0b3fdcf0f44c
Autor:
Jin, Luming1 (AUTHOR), Chen, Chaoyang1 (AUTHOR), Yao, Jianyu1 (AUTHOR), Yu, Zhichen1 (AUTHOR), Bu, Liang1 (AUTHOR) liangbubio@yeah.net
Publikováno v:
Clinical & Experimental Pharmacology & Physiology. Mar2022, Vol. 49 Issue 3, p329-340. 12p. 2 Color Photographs, 1 Chart, 7 Graphs, 1 Map.
Autor:
Jin, Luming1 (AUTHOR), Chen, Chaoyang1 (AUTHOR), Huang, Lipeng1 (AUTHOR), Bu, Liang1 (AUTHOR), Zhang, Libin2 (AUTHOR), Yang, Qiuju3 (AUTHOR) shuoqiyang@hotmail.com
Publikováno v:
Clinical & Experimental Pharmacology & Physiology. Apr2021, Vol. 48 Issue 4, p508-514. 7p. 6 Graphs.
Publikováno v:
Clinical and Experimental Pharmacology and Physiology. 49:329-340
The key N6 methyladenosine (m6 A) RNA methylation regulator is associated with multiple tumor progression. However, the m6 A-associated regulators that influence non-small-cell lung cancer (NSCLC) development have not been fully clarified. The m6 A r
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Clinical and experimental pharmacologyphysiologyREFERENCES. 48(4)
Vasculogenic mimicry (VM) is associated with aggressive cancer cells. Salvianolic acid A (Sal-A), an antioxidant and anti-inflammatory agent, has bioactive properties from Salvia miltiorrhiza Bunge. Current investigation aspired to explore the activi
Autor:
Jin L; Department of Thoracic Surgery, Xiamen University Institute of Chest and Lung Disease, Xiang'an Hospital of Xiamen University, Xiamen, China., Chen C; Department of Thoracic Surgery, Xiamen University Institute of Chest and Lung Disease, Xiang'an Hospital of Xiamen University, Xiamen, China., Yao J; Department of Thoracic Surgery, Xiamen University Institute of Chest and Lung Disease, Xiang'an Hospital of Xiamen University, Xiamen, China., Yu Z; Department of Thoracic Surgery, Xiamen University Institute of Chest and Lung Disease, Xiang'an Hospital of Xiamen University, Xiamen, China., Bu L; Department of Thoracic Surgery, Xiamen University Institute of Chest and Lung Disease, Xiang'an Hospital of Xiamen University, Xiamen, China.
Publikováno v:
Clinical and experimental pharmacology & physiology [Clin Exp Pharmacol Physiol] 2022 Mar; Vol. 49 (3), pp. 329-340. Date of Electronic Publication: 2021 Nov 14.